Treatment of warts by Topical retinoids: An Exploration and meticulosity

Ruchi Tiwari, Gaurav Tiwari, Pranay Wal, Ankita Wal


Warts are clinically skin infections caused by Human Papilloma Virus (HPV). Some warts are painful while others cause frustration in patients. Warts are contagious and need to be diagnosed clinically from the outgrowth of skin. Topical retinoids have clinical use for treatment of chronic skin conditions. Topical retinoids for treatment of skin cancer are tretinoin, the acid form of vitamin A, also known as all-trans retinoic acid, which is the active vitamin A metabolite in several tissues, isotretinoin (13-cis-retinoic acid), and two third-generation retinoids, adapalene and tazarotene. Vitamin A is necessary for the growth and differentiation of epithelial tissues. Retinoids influence the process of vitamin A by interacting with specific cellular and nuclear receptors of skin. In that way retinoids control cell proliferation and differentiation and potentially interfere with the tumor promotion phase of carcinogenesis by inducing apoptosis. Review of medical literatures from past few years revealed monotherapies and combination therapies to eradicate viral infections caused by HPV. Purpose of this review article is to provide general information about warts,
its mechanism and treatment by topical retinoids.


Antiquity of warts, Diagnosis, Topical retinoids and its mechanism of action, Exploration of tretinoin

Full Text:



Skin Problems and Treatments [Internet]. WebMed;

[Cited 2016 July 12]. Available from: http://www.

Bruggink SC, de Koning MN, Gussekloo J, Egberts

PF, Ter Schegget J, Feltkamp MC, Bavinck JN, Quint

WG, Assendelft WJ, Eekhof JA. Cutaneous wartassociated

HPV types: Prevalence and relation with

patient Characteristics. Journal of Clinical Virology

; Nov;55(3):250-5.

Shayanfar N, Hosseini N, Panahi M , Azadmanesh

K, Mohammadpour M, Kadivar M, Mirzaie AZ , Sohrabi

A. Detection of mucosal type human papillomavirus in

cutaneous squamous cell carcinoma in Iran. Pathology

– Research and Practice 2013; 209(2):90-4.

Devi LT, Pathania K. Pregnancy with HPV associated

Viral Warts. MJAFI 2009; July;65:272-3.

Jabeotiska S, Majewski S, Obalek S, Orth G. Cutaneous

Warts. Clinics in dermatology. 1997 May-June;15(3):


Sterling JC, Gibbs S, Haque Hussain SS, Mohd

Mustapa MF, Handfield-Jones SE. British Association

of Dermatologists’ Guidelines for the Management of

Cutaneous Warts. The British Journal of Dermatology

; Oct;171(4):696-712.

Zur Hausen H. Papillomaviruses in the causation of

human cancers- a brief historical account. Virology

; Feb;384(2):260-5.

Parmar D, Shah J. Cutaneous Warts and its Treatment:

A Literature Review. International Journal of Science

and Research 2015; September;4(9):87-89.

Shapiro S, Heremans A, Mays DA, Martin AL, Hernandez-

Medina M, Lanes S. Use of topical tretinoin and the

development of noncutaneous adverse events:

Evidence from a systematic review of the literature. J

Am Acad Dermatol 2011; Dec;65(6):1194-201.

Ouriquea A, Pohlmannb AR, Guterresc SS, Beckd

RCR. Tretinoin-loaded nanocapsules: Preparation,

physicochemical characterization, and photostability

study. International Journal of Pharmaceutics 2008;


Tian Y, Zhong S, Huang A, Pann Y, Wang X. Large pore

size FeNi carbon microspheres: Synthesis and tretinoin

adsorption behavior. Materials Letters. 2015;141:10–

Tashtoush BM, Jacobson EL, Jacobson MK. A rapid HPLC

method for simultaneous determination of tretinoin

and isotretinoin in dermatological formulations. Journal

of Pharmaceutical and Biomedical Analysis. J Pharm

Biomed Anal 2007; Feb;43(3):859-64.

Ascenso A, Salgado A, Euleterio C, Praca FG, Bentley

MV, Marques HC, Oliveira H, Santos C, Simoes S. In

vitro and in vivo topical delivery studies of tretinoinloaded

ultradeformable vesicles. European Journal of

Pharmaceutics and Biopharmaceutics 2014; 88(1):48–

Manconi M, Sinico C, Caddeo C, Vila AO, Valenti

D, Fadda AM. Penetration enhancer containing

vesicles as carriers for dermal delivery of tretinoin.

Int J Pharm 2011; Jun;412(1-2):37-46.

Berger R, Rizer R, Barba A, Wilson D, Stewart

D, Grossman R, Nighland M, Weiss J. Tretinoin Gel

Microspheres 0.04% Versus 0.1% in Adolescents and

Adults with Mild to Moderate AcneVulgaris: A 12-Week,

Multicenter, Randomized, Double-Blind, Parallel-Group,

Phase IV Trial. Clin Ther 2007; Jun;29(6):1086-97.

Micali G, Lacarrubb F, Nasca MR, Schwartz RA. Topical

pharmacotherapy for skin cancer. J Am Acad Dermatol

; June;70(6):965.e1-965.e10.

Leon H. Kircik MD. Evaluating Tretinoin Formulations

in the Treatment of Acne. J Drugs Dermatol 2014;


Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid

nanoparticles (SLN) of tretinoin: Potential in topical

delivery. International Journal of Pharmaceutics


Manconi M, Sinico C, Valenti D, Lai F, Fadda AM.

Niosomes as carriers for tretinoin III. A study into the

in vitro cutaneous delivery of vesicle-incorporated

tretinoin. International Journal of Pharmaceutics


Lai F, Pireddu R, Corrias F, Fadda AM, Valenti D, Pini

E, Sinico C. Nanosuspension improves tretinoin

photostability and deliveryto the skin. International

Journal of Pharmaceutics 2013;458:104 -09.


  • There are currently no refbacks.

Copyright (c) 2018 Journal of Drug Discovery and Development

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.